Uncategorized
Ocular Therapeutix strategizes design for phase 3 trials of OTX-TP
Ocular Therapeutix is planning to initiate the first of two phase 3 clinical trials of OTX-TP for the treatment of glaucoma and ocular hypertension in the third quarter based on feedback from a recent meeting with the FDA, the company announced in a press release. The planned design for the phase 3 trials includes an OTX-TP (sustained release travoprost) treatment arm and a placebo-controlled comparator arm that would use a non-drug eluting hydrogel-based intracanalicular depot.